medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2024, Número 2

<< Anterior Siguiente >>

Rev Biomed 2024; 35 (2)


Aspartato aminotransferasa salival biomolécula diagnóstica de periodontitis como puente de interacción multidisciplinaria

Zamora-Ginez I, Baez-Duarte BG, Monjaras E, Franco-Romero G, Peralta-Prado DJ, Briones-Montiel A

Idioma: Español
Referencias bibliográficas: 36
Paginas: 76-84
Archivo PDF: 175.56 Kb.


RESUMEN

Introducción. Es necesaria una adecuada interacción multidisciplinaria entre médicos y profesionales de la salud bucodental para disminuir las repercusiones de la enfermedad periodontal.
Objetivo. Determinar si aspartato aminotransferasa salival (AST) es mejor biomolécula diagnóstica de periodontitis comparada con AST sérica e Interleucina- 6 (IL-6) y factor de necrosis tumoralalfa (TNF-α) salivales y séricas.
Material y Método. Estudio de metodología mixta, compuesta por dos subestudios, el primero, experimental, comparativo, transversal, retrospectivo para determinar la capacidad diagnóstica de AST, IL-6 y TNF-α salivales y séricas en sujetos sin diagnóstico de periodontitis que acuden al servicio de medicina general y el segundo, experimental, comparativo, longitudinal, para confirmar la capacidad diagnóstica de AST salival (ASTsa), antes y después de tratamiento periodontal en sujetos que acuden al servicio de salud bucodental. El diagnóstico de periodontitis se determinó mediante el índice de Extensión y Severidad (IES).
Resultados. Solo los niveles de ASTsa fueron diferentes entre sujetos sin y con periodontitis (p ‹ 0.0005), los cuales correlacionaron con la extensión (r = 0.410, p ‹ 0.0005) y severidad (r = 0.428, p ‹ 0.0005) del IES, y presentaron un punto de corte de 16.0 UI / mL con alta capacidad discriminativa (Área bajo la curva = 0.936, IC 95 %, 0.864 - 1,000; p ‹ 0.001). Además, posterior a tratamiento periodontal los niveles de ASTsa disminuyeron (116.9 ± 76.2. U/L vs 58.8 ± 47.0 U/L, p ‹ 0.001).
Conclusión. ASTsa es la mejor biomolécula diagnóstica de periodontitis que podría utilizarse como puente de interacción multidisciplinaria.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bains VK, Chandra H, Jamaluddin K, Bains R. Awarenessamong health care professionals regarding interrelationshipbetween diabetes mellitus and periodontal diseases: A steptowards interprofessional collaborative practice. Asian J OralHeal Allied Sci. 2020 Dic; 10(10): 10. https://doi.org/10.25259/AJOHAS_16_2020

  2. Siddiqi A, Zafar S, Sharma A, Quaranta A. Diabetes mellitusand periodontal disease: The call for interprofessional educationand interprofessional collaborative care - A systematic reviewof the literature. J Interprof Care. 2022 Ene; 36(1): 93–101.https://doi.org/10.1080/13561820.2020.1825354

  3. Variath PT, Biniraj K, Rishi E, Tony PP, Priya J, Divyasree K.The effect of periodontal therapy on glycaemic level in patientswith controlled type 2 diabetes mellitus on sulfonylurea oralhypoglycaemic agents. Int J Appl Dent Sci. 2022 Ene; 8(1): 466–70. https://doi.org/10.22271/oral.2022.v8.i1g.1464

  4. Herrera D, Sanz M, Shapira L, Brotons C, Chapple I, FreseT, et al. Association between periodontal diseases andcardiovascular diseases, diabetes and respiratory diseases:Consensus report of the Joint Workshop by the EuropeanFederation of Periodontology (EFP) and the European arm ofthe World Organization. J Clin Periodontol. 2023 Ene; 50(6):819–41. https://doi.org//10.1111/jcpe.13807

  5. Sadek K, El Moshy S, Radwan I, Rady D, Abbass M, El-Rashidy A, et al. Molecular basis beyond Interrelated boneresorption/regeneration in periodontal diseases: A ConciseReview. Int J Mol Sci. 2023 Feb; 24(5): 4599. https://doi.org//10.3390/ijms24054599

  6. Giraldo A, Roldan N, Duque A, Navarro JC. Índice deextensión y severidad (ESI) como parámetro para describir larespuesta a la terapia clínica en el manejo de la enfermedadperiodontal. CES Odontol. 2006 Dic; 19(2): 17–24. https://pesquisa.bvsalud.org/portal/resource/pt/lil-454869

  7. Dhingra K, Vandana KL. Indices for measuring periodontitis:A literature review. Int Dent J. 2011 Abr; 61: 76–84. https://doi.org//10.1111/j.1875-595X.2011.00018.x

  8. Manandhar S, Prasanth T, Satisha TS, Kumar P. Salivarydiagnostic biomarker for periodontal disease - A review. JDent Spec. 2021 Oct; 9(1): 7–12. https://doi.org//10.18231/j.jds.2021.003

  9. Alsaykhan K, Khan NS, Aljumah MI, Albughaylil AS.comparative evaluation of salivary enzyme in patients withgingivitis and periodontitis: A clinical-biochemical study.Cureus. 2022 Ene; 14(1): e20991. https://doi.org//10.7759/cureus.20991

  10. AlMoharib HS, AlMubarak A, AlRowis R, GeevargheseA, Preethanath RS, Anil S. Oral fluid based biomarkers inperiodontal disease: part 1. Saliva. JIOH. 2014 Jul; 6(4):95–103.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148585/

  11. Todorovic T, Dozic I, Vicente-Barrero M, Ljuskovic B, PejovicJ, Marjanovic M, et al. Salivary enzymes and periodontaldisease. Medi oral, patol oral cir bucal. 2006 Mar; 11(2): E115-9. http://www.ncbi.nlm.nih.gov/pubmed/16505786

  12. Shinde H, Gaddale R, Ilangovan K. Use of saliva aspartateaminotransferase in diagnosing periodontal disease: A clinicaland biochemical study. J Dr NTR Univ Heal Sci. 2022Ago; 11(2): 107. https://doi.org//10.4103/JDRNTRUHS.JDRNTRUHS_90_20

  13. Figueredo CM, Lira-Junior R, Love RM. T and B cells inperiodontal disease: New functions in a complex scenario. IntJ Mol Sci. 2019 Ago; 20(16): 1–13. https://doi.org//10.3390/ijms20163949

  14. Sarasati A, Jonarta AL. Potential targets of phytochemicalimmunomodulatory therapy in periodontitisimmunopathogenesis: A narrative review. Saudi DentJ. 2023 Dic; 35(8): 920–8. https://doi.org//10.1016/j.sdentj.2023.08.005

  15. Gümüş P, Nizam N, Lappin DF, Buduneli N. saliva andserum levels of B‐cell activating factors and Tumor NecrosisFactor‐α in patients with periodontitis. J Periodontol. 2014Feb; 85(2): 270–80. http://www.joponline.org/doi/10.1902/jop.2013.130117

  16. Kibune R, Muraoka K, Morishita M, Ariyoshi W, Awano S.Relationship between dynamics of TNF-α and Its solublereceptors in saliva and periodontal health state. Dent J. 2022Feb; 10(2): 25. https://doi.org//10.3390/dj10020025

  17. Bagan L, Sáez GT, Tormos MC, Labaig-Rueda C, Murillo-Cortes J, Bagan J V. Salivary and serum interleukin-6 levels inproliferative verrucous leukoplakia. Clin Oral Invest [Internet].2016 May; 20(4): 737–43. https://doi.org//10.1007/s00784-015-1551-z

  18. Carrillo De Albornoz Sainz A, García Kass A, BasconesMartínez A. Papel de la IL-6 TNF-α en la enfermedadperiodontal. Av Periodoncia. 2006 Ago; 18(2): 83–9. http://scielo.isciii.es/pdf/peri/v18n2/original2.pdf

  19. Ridha HS, Kadri ZHM. Assessment of liver enzymes in salivaand serum of Iraqi patients with chronic periodontitis disease.J Biotechnol Res Cent . 2020 Ene; 14(1): 20–4. https://doi.org//10.24126/jobrc.2020.14.1.584

  20. MedlinePlus [Internet]. AST Test [Internet]. Bethesda (MD):National Library of Medicine (US). 2022 [citado 2023 Ago16]. https://medlineplus.gov/lab-tests/ast-test/#:~:text=An%20AST%20blood%20test%20is,help%20diagnose%20other%20health%20conditions.

  21. Brailo V, Vucicevic-Boras V, Lukac J, Biocina-LukendaD, Alajbeg-Zilic I, Milenovic A, et al. Salivary and seruminterleukin 1 beta, interleukin 6 and tumor necrosis factoralpha in patients with leukoplakia and oral cancer. Medi OralPatol Oral Cir Bucal. 2012 Ene; 17(1): e10–5. https://doi.org//10.4317/medoral.17323

  22. Costa PP, Trevisan GL, Macedo GO, Palioto DB, SouzaSLS, Grisi MFM, et al. salivary interleukin‐6, matrixmetalloproteinase‐8, and osteoprotegerin in patients withperiodontitis and diabetes. J Periodontol. 2010 Mar; 81(3): 384–91. http://www.joponline.org/doi/10.1902/jop.2009.090510

  23. Jung Y, Kim J-H, Shin A-R, Song K-B, Amano A, Choi Y-H.association of adiposity with periodontitis and metabolicsyndrome: from the third national health and nutritionexamination survey of United States. Int J Env Res PublicHeal. 2023 Ene; 20(3): 2533. https://doi.org//10.3390/ijerph20032533

  24. Carlos JP, Wolfe MD, Kingman A. The extent and severityindex: a simple method for use in epidemiologic studies ofperiodontal disease. J Clini Periodontol. 1986 May; 13(5): 500–5. http://doi.wiley.com/10.1111/j.1600-051X.1986.tb01497.x

  25. Wiebe CB, Putnins EE. The periodontal disease classificationsystem of the American Academy of periodontology-an update.J Can Dent Assoc. 2000 Dic; 66(11): 594–7. https://www.cdaadc.ca/jcda/vol-66/issue-11/594.pdf

  26. Cerda J, Cifuentes L. Uso de curvas ROC en investigaciónclínica. Aspectos teórico-prácticos. Rev Chil Infectol.2012 Abr; 29(2): 138–41. https://doi.org//10.4067/S0716-10182012000200003

  27. Marouf N, Cai W, Said KN, Daas H, Diab H, Chinta VR, et al.Association between periodontitis and severity of COVID‐19infection: A case–control study. J Clin Periodontol. 2021 Abr;48(4): 483–91. https://onlinelibrary.wiley.com/doi/10.1111/jcpe.13435

  28. Risteska N, Poposki B, Ivanovski K, Dirjanska K, Ristoska S,Saveski M. Diagnostic and prognostic markers of periodontaldisease. PRILOZI. 2021 Dic; 42(3): 89–95. https://doi.org//10.2478/prilozi-2021-0039

  29. Luke R, Khan SN, Iqbal PS, Soman RR, ChakkarayanJ, Krishnan V. Estimation of specific salivary enzymaticbiomarkers in individuals with gingivitis and chronic: A Clinicaland Biochemical Study. J Int Oral Heal. 2015 Sep; 7(9): 54–7.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589720/

  30. Kudva P, Saini N, Kudva H, Saini V. To estimate salivaryaspartate aminotransferase levels in chronic gingivitis andchronic periodontitis patients prior to and following nonsurgicalperiodontal therapy: A clinico-biochemical study.J Indian Soc Periodontol [Internet]. 2014;18(1):53. https://pubmed.ncbi.nlm.nih.gov/24744545/

  31. Caliaperoumal SK, Gnanasekaran H, Kaliamoorthy S.Comparison of lactate dehydrogenase (LDH), aspartateaminotransferase (AST) and alkaline phosphatase (ALP)in saliva of normal, gingivitis and periodontitis patients.Int J Dent Oral Sci. 2021 Nov; 8(88): 5164–7. https://doi.org//10.19070/2377-8075-210001037

  32. Abdel Kader K, Elhabbak S, Assadawy M. Evaluation of somesalivary enzymes as a diagnostic biomarker for progressionof periodontal disease. Al-Azhar J Dent Sci. 2021 Abr; 24(2):175–86. https://doi.org//10.21608/ajdsm.2020.34246.1076

  33. Nomura Y, Tamaki Y, Tanaka T, Arakawa H, Tsurumoto A,Kirimura K, et al. Screening of periodontitis with salivaryenzyme tests. J Oral Sci. 2006 Dic; 48(4): 177–83. https://doi.org//10.2334/josnusd.48.177

  34. Fujii T, Aoyama N, Kida S, Taniguchi K, Yata T, Minabe M, etal. Associations between periodontal status and liver functionin the japanese population: A cross-sectional study. J Clin Med.2023 Jul; 12(14): 4759. https://doi.org//10.3390/jcm12144759

  35. Huang Y, Zhang Q, Guo Z, Deng G, Chen R, Zheng Y. Potentialnoninvasive biomarkers for the malignant transformationof oral leukoplakia: A systematic review and meta‐analysis.Cancer Med. 2023 Jul; 12(13): 14718–30. https://onlinelibrary.wiley.com/doi/10.1002/cam4.6095

  36. Chen D, Zhong L, Li Y, He R, Ding C, Chen X, et al. Changes inserum inflammatory factor interleukin-6 levels and pathologyof carotid vessel walls of rats with chronic periodontitis anddiabetes mellitus after the periodontal intervention. Saudi JBiol Sci. 2020 Jun; 27(6): 1679–84. https://doi.org//10.1016/j.sjbs.2020.04.029




2020     |     www.medigraphic.com